Dalpiciclib verus placebo plus fulvestrant in HR + /Her2- advanced breast cancer that relapsed or progressed on previous endocrine thearpy (DAVNA-1): A multicenter, randomized, phase 3 study - Xu, B (ASCO, 2021)